SBIR/STTR Research Award

A Novel Workflow to Screen for Illicit Drug Exposure in Newborns

Award identifier a47234c9650baee783de649a5f0bb334e0b7b9eab9e02abdcd9e8943b50dee7eAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$224,999

Program and phase

SBIR · Phase I

Award year

2019

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
BAEBIES, INC.
Proposal award date
2019-09-30
Contract end date
2020-06-30
UEI
NZSZBQ9B84T1
Solicitation number
DA19-019
Topic code
NIDA

Research abstract

ABSTRACT A Novel Workflow to Screen for Illicit Drug Exposure in NewbornsRFA DANeonatal abstinence syndromeNASrefers to a spectrum of withdrawal symptoms in newborns who were exposed to illicit or addictive substances in uteroBabies with NAS have higher rates of fetal anomaliescongenital malformationsgrowth restrictionischemic placental complicationsand perinatal issuespreterm deliverypoor feedingsleep difficultiesdiarrheaseizureswhich together raise the risk for adverse long term outcomesRates of NAS have skyrocketed during the last decade and estimates suggest thatof mothers use at least one addictive drug during their pregnancyTo address this public health crisismultiple groups including the American College of Obstetrics and Gynecology and the American Academy of Pediatrics recommend universal screening of substance use in pregnancy using standardized behavioral scoring toolsUnfortunatelysuch tools are often biased due to subjective scoring or self reporting errorsand fail to identify babies who did not receive proper prenatal careEarly identification of NAS is essential for referral of affected babies for interventionsincluding pharmacological treatments and behavioral social support for the familySelect hospitals in Ohio and Texas are already engaged in universal toxicology based newborn screeningNBSfor NASand several state public health programs are evaluating feasibility to incorporate NAS screening into their standard NBS panelsWhile toxicology NBS for NAS is expanding in the U Sseveral factors currently restrict the growth of such programsThese includelimited sensitivity and short history of exposure with existing tests for urine and blood sampleschallenging methodologies for meconium sample processinglimited testing options for meconium samplesand long turnaround times for the few existing meconium testsThe potential consequences of delayed or otherwise insufficient NAS screening include increased errors and or delays in pharmacologic treatmentshigh costs associated with unnecessary hospitalizationand increased risk for misdiagnosisTo combat these challengeswe propose a novel workflow that will enable rapid toxicology screening of urine or meconium samples in the hospitalOur system will pair a simple sample preparation protocol with a high sensitivity panel of homogeneous enzyme immunoassays recognizing five common classes of drugsfentanylmorphineamphetamine methamphetaminecocaineand benzodiazepinesThe tests will be automated on an innovative digital microfluidic analyzer with a total time to resultincluding sample processing timeof underhoursThe product of this research meets the goals of RFA DAto developinnovative methods to identify and treat newborns exposed to opioidsand will furthermore support the goals of the American Academy of Pediatrics to expand high sensitivity NAS screeningThe potential benefits from implementation of our protocol include reduced length of hospitalization for unaffected newbornsaccelerated time to confirmatory resultsfaster resolution of acute withdrawal symptomsand improved referral to family maternal support services PROJECT NARRATIVE Neonatal abstinence syndromeNASrefers to the numerous and diverse withdrawal symptoms in newborns who were exposed to illicit or addictive substances in uteroEarly identification of NAS through neonatal screeningobservational and toxicological testing in tandemis essential to diagnosing affected babies for appropriate interventionsincluding pharmacological treatments and behavioral social support for the familyOur proposed novel testing platform will enable rapid toxicology screening of urine or meconium samples in the hospital to recognize five classes of drugs commonly impacting NAS newbornsfentanylmorphineamphetaminescocaineand benzodiazepinesImprovements to the diagnosis process through our workflow include reduced length of hospitalization for unaffected newbornsutilization of sample types with increased sensitivityaccelerated time to confirmatory resultsfaster resolution of acute withdrawal symptomsand improved referral to family maternal support services

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

45 SBIR/STTR records share this UEI (2014–2025). Reported award amounts total $42,450,057. Reported amounts are not federal obligations.

Phases: Phase II, Phase I, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.